JP2014534222A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534222A5
JP2014534222A5 JP2014539297A JP2014539297A JP2014534222A5 JP 2014534222 A5 JP2014534222 A5 JP 2014534222A5 JP 2014539297 A JP2014539297 A JP 2014539297A JP 2014539297 A JP2014539297 A JP 2014539297A JP 2014534222 A5 JP2014534222 A5 JP 2014534222A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
group
represents hydrogen
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534222A (ja
JP6091513B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/071352 external-priority patent/WO2013064450A1/en
Publication of JP2014534222A publication Critical patent/JP2014534222A/ja
Publication of JP2014534222A5 publication Critical patent/JP2014534222A5/ja
Application granted granted Critical
Publication of JP6091513B2 publication Critical patent/JP6091513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539297A 2011-11-02 2012-10-29 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 Active JP6091513B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187553.0 2011-11-02
EP11187553 2011-11-02
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Publications (3)

Publication Number Publication Date
JP2014534222A JP2014534222A (ja) 2014-12-18
JP2014534222A5 true JP2014534222A5 (cg-RX-API-DMAC7.html) 2015-12-17
JP6091513B2 JP6091513B2 (ja) 2017-03-08

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539297A Active JP6091513B2 (ja) 2011-11-02 2012-10-29 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法

Country Status (34)

Country Link
US (4) US8759349B2 (cg-RX-API-DMAC7.html)
EP (1) EP2773633B1 (cg-RX-API-DMAC7.html)
JP (1) JP6091513B2 (cg-RX-API-DMAC7.html)
KR (1) KR102006612B1 (cg-RX-API-DMAC7.html)
CN (2) CN106279110B (cg-RX-API-DMAC7.html)
AP (1) AP2014007670A0 (cg-RX-API-DMAC7.html)
AU (1) AU2012331274B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010583A2 (cg-RX-API-DMAC7.html)
CA (1) CA2854217C (cg-RX-API-DMAC7.html)
CL (1) CL2014001047A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940429A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120974T1 (cg-RX-API-DMAC7.html)
DK (1) DK2773633T3 (cg-RX-API-DMAC7.html)
EA (1) EA025158B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP14001929A (cg-RX-API-DMAC7.html)
ES (1) ES2645744T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186880B (cg-RX-API-DMAC7.html)
HR (1) HRP20171614T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034929T2 (cg-RX-API-DMAC7.html)
IL (1) IL232035A (cg-RX-API-DMAC7.html)
LT (1) LT2773633T (cg-RX-API-DMAC7.html)
ME (1) ME02905B (cg-RX-API-DMAC7.html)
MX (1) MX348522B (cg-RX-API-DMAC7.html)
NO (1) NO2773633T3 (cg-RX-API-DMAC7.html)
PE (1) PE20141607A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500970B1 (cg-RX-API-DMAC7.html)
PL (1) PL2773633T3 (cg-RX-API-DMAC7.html)
PT (1) PT2773633T (cg-RX-API-DMAC7.html)
RS (1) RS56498B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401907TA (cg-RX-API-DMAC7.html)
SI (1) SI2773633T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000180A1 (cg-RX-API-DMAC7.html)
UA (1) UA115868C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013064450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
PL2773633T3 (pl) * 2011-11-02 2018-01-31 Boehringer Ingelheim Int Związki heterocykliczne, leki zawierające wymienione związki, ich zastosowanie i procesy ich wytwarzania
KR20160054460A (ko) * 2013-07-02 2016-05-16 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 낭성 섬유증의 치료를 위한 화합물
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
SG11201703284XA (en) 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
HK1246718A1 (zh) * 2015-01-07 2018-09-14 斯克利普斯研究所 用於治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (cg-RX-API-DMAC7.html) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
AU774865B2 (en) 1999-07-19 2004-07-08 University Of North Carolina At Chapel Hill, The Conjugates of sodium channel blockers and methods of using the same
WO2001052902A1 (en) 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
WO2006023573A2 (en) 2004-08-18 2006-03-02 Johnson Michael R Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008013557A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
ATE499363T1 (de) * 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
EP2285785B1 (en) * 2008-05-13 2012-09-05 Novartis AG 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
CN104024231A (zh) 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法
PL2773633T3 (pl) * 2011-11-02 2018-01-31 Boehringer Ingelheim Int Związki heterocykliczne, leki zawierające wymienione związki, ich zastosowanie i procesy ich wytwarzania

Similar Documents

Publication Publication Date Title
JP2014534222A5 (cg-RX-API-DMAC7.html)
JP2014530801A5 (cg-RX-API-DMAC7.html)
HRP20171614T1 (hr) Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
UA104997C2 (uk) Аміди азотвмісних насичених гетероциклів та 3,5-діаміно-6-хлор-2-піразинкарбонової кислоти як лікарський засіб
JP2009532417A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2016534088A5 (cg-RX-API-DMAC7.html)
JP2011530493A5 (cg-RX-API-DMAC7.html)
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
JP2008533191A5 (cg-RX-API-DMAC7.html)
JP2014097964A5 (cg-RX-API-DMAC7.html)
JP2014515351A5 (cg-RX-API-DMAC7.html)
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
CA2540174A1 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
JP2005516067A5 (cg-RX-API-DMAC7.html)
HRP20191339T1 (hr) Novi anelirani fenoksiacetamidi
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
WO2006018718A3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
CA2471578A1 (en) Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
WO2008012290A3 (en) Quinuclidine derivatives as m3 antagonists
PE20110829A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos
JP2016532677A5 (cg-RX-API-DMAC7.html)
JP2015526453A5 (cg-RX-API-DMAC7.html)
JP2016526023A5 (cg-RX-API-DMAC7.html)